Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Gains from Sales and Divestitures (2020 - 2022)

AdaptHealth (AHCO) has 3 years of Gains from Sales and Divestitures data on record, last reported at $461000.0 in Q3 2022.

  • For Q3 2022, Gains from Sales and Divestitures rose 37.61% year-over-year to $461000.0; the TTM value through Sep 2022 reached $461000.0, up 37.61%, while the annual FY2021 figure was $556000.0, 344.8% up from the prior year.
  • Gains from Sales and Divestitures reached $461000.0 in Q3 2022 per AHCO's latest filing, up from $350000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $556000.0 in Q4 2021 and bottomed at $15417.0 in Q1 2020.
  • Average Gains from Sales and Divestitures over 3 years is $219219.7, with a median of $156000.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 680.0% in 2021, then soared 37.61% in 2022.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $125000.0 in 2020, then surged by 344.8% to $556000.0 in 2021, then dropped by 17.09% to $461000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $461000.0 in Q3 2022, $350000.0 in Q2 2022, and $230000.0 in Q1 2022.